Literature DB >> 36035608

How reliable are the multiple comparison methods for odds ratio?

Ayfer Ezgi Yilmaz1.   

Abstract

The homogeneity tests of odds ratios are used in clinical trials and epidemiological investigations as a preliminary step of meta-analysis. In recent studies, the severity or mortality of COVID-19 in relation to demographic characteristics, comorbidities, and other conditions has been popularly discussed by interpreting odds ratios and using meta-analysis. According to the homogeneity test results, a common odds ratio summarizes all of the odds ratios in a series of studies. If the aim is not to find a common odds ratio, but to find which of the sub-characteristics/groups is different from the others or is under risk, then the implementation of a multiple comparison procedure is required. In this article, the focus is placed on the accuracy and reliability of the homogeneity of odds ratio tests for multiple comparisons when the odds ratios are heterogeneous at the omnibus level. Three recently proposed multiple comparison tests and four homogeneity of odds ratios tests with six adjustment methods to control the type-I error rate are considered. The reliability and accuracy of the methods are discussed in relation to COVID-19 severity data associated with diabetes on a country-by-country basis, and a simulation study to assess the powers and type-I error rates of the tests is conducted.
© 2022 Informa UK Limited, trading as Taylor & Francis Group.

Entities:  

Keywords:  COVID-19; Homogeneity of odds ratios; meta-analysis; multiple comparisons; statistical power; type-I error

Year:  2022        PMID: 36035608      PMCID: PMC9415621          DOI: 10.1080/02664763.2022.2104229

Source DB:  PubMed          Journal:  J Appl Stat        ISSN: 0266-4763            Impact factor:   1.416


  26 in total

1.  Exact and asymptotic tests for homogeneity in several 2 x 2 tables.

Authors:  I M Reis; K F Hirji; A A Afifi
Journal:  Stat Med       Date:  1999-04-30       Impact factor: 2.373

Review 2.  Strategies for comparing treatments on a binary response with multi-centre data.

Authors:  A Agresti; J Hartzel
Journal:  Stat Med       Date:  2000-04-30       Impact factor: 2.373

3.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

4.  Statistical aspects of the analysis of data from retrospective studies of disease.

Authors:  N MANTEL; W HAENSZEL
Journal:  J Natl Cancer Inst       Date:  1959-04       Impact factor: 13.506

5.  We should not pool diagnostic likelihood ratios in systematic reviews.

Authors:  Aeilko H Zwinderman; Patrick M Bossuyt
Journal:  Stat Med       Date:  2008-02-28       Impact factor: 2.373

6.  A general introduction to adjustment for multiple comparisons.

Authors:  Shi-Yi Chen; Zhe Feng; Xiaolian Yi
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

7.  A Monte Carlo investigation of homogeneity tests of the odds ratio under various sample size configurations.

Authors:  M P Jones; T W O'Gorman; J H Lemke; R F Woolson
Journal:  Biometrics       Date:  1989-03       Impact factor: 2.571

8.  Beta blockade during and after myocardial infarction: an overview of the randomized trials.

Authors:  S Yusuf; R Peto; J Lewis; R Collins; P Sleight
Journal:  Prog Cardiovasc Dis       Date:  1985 Mar-Apr       Impact factor: 8.194

9.  High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation.

Authors:  Arthur Simonnet; Mikael Chetboun; Julien Poissy; Violeta Raverdy; Jerome Noulette; Alain Duhamel; Julien Labreuche; Daniel Mathieu; Francois Pattou; Merce Jourdain
Journal:  Obesity (Silver Spring)       Date:  2020-06-10       Impact factor: 9.298

10.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.

Authors:  Zunyou Wu; Jennifer M McGoogan
Journal:  JAMA       Date:  2020-04-07       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.